LALPATHLAB1,912.00

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,045 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
LALPATHLAB
FY26
METROPOLIS
FY26
VIJAYA
FY26
THYROCARE
FY26
Peer
Median
Valuation — at last close
P/E63.23×64.74×89.41×54.33×64.74× -2%
P/B12.61×8.09×16.16×15.15×15.15× -17%
EV/EBITDA40.10×30.33×45.10×33.17×33.17× +21%
Market Cap₹32,045 Cr₹12,336 Cr₹15,465 Cr₹8,882 Cr₹12,336 Cr +160%
Growth
Revenue CAGR 3Y11.06%12.75%21.03%16.33%16.33% -32%
Revenue CAGR 5Y11.81%10.52%16.66%10.88%10.88% +9%
Net Income CAGR 3Y28.35%10.06%26.62%36.27%26.62% +6%
Revenue YoY (latest Q)19.10%16.62%22.83%24.34%22.83% -16%
Net Income YoY (latest Q)27.24%25.72%37.61%34.06%34.06% -20%
Profitability
EBITDA Margin28.32%24.36%41.38%31.61%31.61% -10%
Net Income Margin18.45%11.62%21.24%19.64%19.64% -6%
Return on Common Equity19.86%12.46%18.07%27.82%18.07% +10%
Return on Capital Employed23.03%14.81%17.72%31.92%17.72% +30%
Return on Assets16.20%8.94%11.48%21.79%11.48% +41%
Credit & Quality
Total Debt/Equity0.00×0.01×0.00×0.00×0.00×
Interest Coverage27.22×10.88×7.38×72.66×10.88× +150%
Scale — latest FY
Revenue / Total Income₹2,763 Cr₹1,646 Cr₹814 Cr₹829 Cr₹829 Cr +233%
Net Income₹510 Cr₹191 Cr₹173 Cr₹163 Cr₹173 Cr +195%
Total Assets₹3,146 Cr₹2,138 Cr₹1,507 Cr₹747 Cr₹1,507 Cr +109%
EPS₹30.24₹9.19₹16.81₹10.27₹10.27 +194%
Book Value per Share₹151.63₹73.53₹93.02₹36.82₹73.53 +106%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.